According to filings with the U.S. Securities and Exchange Commission, Gilgamesh Pharma is raising up to $6,090,946.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Gilgamesh Pharma
Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access.

To learn more about Gilgamesh Pharma, visit https://www.gilgameshpharmaceutical.com/
Gilgamesh Pharma Linkedin Page: https://www.linkedin.com/company/gilgamesh-pharma/

Contact:
Jonathan Sporn, Chief Executive Officer
929-723-4861
https://www.linkedin.com/in/jonathan-sporn-4ba7802/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.